Compare Hims and Hers Health Inc (HIMS) vs Starbucks Corp (SBUX) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

Starbucks (SBUX) trades at $93.58, down 2.63% on the day, as the company navigates a strategic restructuring with 250 North American store closures. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, SBUX maintains stable revenue growth but faces margin compression, with net income declining to $1.86B in 2025. Analyst consensus remains positive with a $115.50 price target, though recent news highlights operational challenges and geopolitical tensions.

The outlook for SBUX balances near-term headwinds from restructuring costs against long-term growth potential in international markets. Investment opportunities include strong brand equity and dividend consistency, while risks involve labor relations, Chinese market exposure, and execution of the store optimization strategy. The current valuation at 53.88x P/E requires sustained earnings recovery to justify upside.